The Company anticipates filing its NDA for GTx-104 in the second quarter of 2025. Acceptance of the NDA will be subject to the FDA’s review of the complete filing.

DataStrike, a leader in data infrastructure managed services, announced today that President Rob Brown and CEO Buddy Flerl will speak at two prominent technology conferences this April. Flerl and ...

Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), today announces that it has successfully secured ...

Epson today announced it will be showcasing its wide range of digital printing solutions at ISA Sign Expo, the preeminent event for the sign, graphics, print, and visual communications industry from ...

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an unmet need in personalized cancer treatment, offering new hope for patients with limited options. As clinical ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.

The report "Defense Platforms and Systems Outlook 2025: Emerging Technologies, Evolving Disruptions, Outlook and Growth Opportunities" ...